Scarica l'app Stockscreener
727.20
2.55%
-19.00
Dopo l'orario di chiusura:
727.00
-0.20
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$746.20
Aprire:
$733.19
Volume 24 ore:
8.26M
Relative Volume:
2.64
Capitalizzazione di mercato:
$683.37B
Reddito:
$40.86B
Utile/perdita netta:
$8.37B
Rapporto P/E:
134.19
EPS:
5.4193
Flusso di cassa netto:
$-2.28B
1 W Prestazione:
-12.64%
1M Prestazione:
-20.78%
6M Prestazione:
-5.56%
1 anno Prestazione:
+22.90%
Intervallo 1D:
$711.40
$734.00
Intervallo di 1 settimana:
$711.40
$833.99
Portata 52W:
$561.65
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Cramer's Lightning Round: Eli Lilly is a buy - NBC Philadelphia
Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters
Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha
Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company
Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive
Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa
Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Yahoo Finance
Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha
3 Growth Stocks You Can Buy Right Now Without Any Hesitation - The Motley Fool
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette
Eli Lilly: positive results for tirzepatide - Marketscreener.com
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360
Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Lilly Sues HHS for Ending Planned 340B Drug Program Cash Rebates - Bloomberg Law
Eli Lilly sues to change hospital drug discount payments, WSJ reports - TipRanks
Eli Lilly and Co (NYSE:LLY) Sues Federal Health Agency over Hospital Drug Discounts - TipRanks
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program - Yahoo! Voices
Eli Lilly: sues US federal agency - Marketscreener.com
Lilly sues US agency over blocking of drug-rebate program - Reuters
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead? - The Motley Fool
Lilly Statement on New 340B Litigation - Investors | Eli Lilly and Company
ELI LILLY AND COMPANY - Marketscreener.com
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows - Verywell Health
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows - Benzinga
Lilly expands research in Singapore with focus on sleep quality - Indianapolis Business Journal
Eli Lilly Stock: Is LLY Stock A Sell After Its Disastrous Third-Quarter Report? - Investor's Business Daily
Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new $42m hub in S’pore - The Straits Times
Eli Lilly: conclusive phase III trial on tirzepatide - Marketscreener.com
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes - Clinical Trials Arena
Lilly Expands Research in Singapore With Focus on Sleep Quality - BNN Bloomberg
Eli Lilly's Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Long-Term Study - Yahoo Finance
Ozempic MDL Plaintiffs Say Eli Lilly, Novo Nordisk Hid Risks - Law360
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks - Marketscreener.com
Eli Lilly's New Drug Shows Promise In Diabetes Prevention - Finimize
Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits - Seeking Alpha
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks - Investors | Eli Lilly and Company
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free - Reuters.com
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years - FiercePharma
Eli Lilly's SWOT analysis: biopharmaceutical giant's stock poised for growth - Investing.com
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Ex-Dividend Reminder: U.S. Physical Therapy, MMM and Eli Lilly - Nasdaq
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? - The Motley Fool
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.90%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):